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Abstract
Background: 18F-THK5351 is a quinoline-derived tau imaging agent with high affinity to paired helical filaments
(PHF). However, high levels of 18F-THK5351 retention in brain regions thought to contain negligible concentrations
of PHF raise questions about the interpretation of the positron emission tomography (PET) signals, particularly given
previously described interactions between quinolone derivatives and monoamine oxidase B (MAO-B). Here, we
tested the effects of MAO-B inhibition on 18F-THK5351 brain uptake using PET and autoradiography.
Methods: Eight participants (five mild cognitive impairment, two Alzheimer’s disease, and one progressive
supranuclear palsy) had baseline 18F-AZD4694 and 18F-THK5351 scans in order to quantify brain amyloid and PHF
load, respectively. A second 18F-THK5351 scan was conducted 1 week later, 1 h after a 10-mg oral dose of
selegiline. Three out of eight patients also had a third 18F-THK5351 scan 9–28 days after the selegiline
administration. The primary outcome measure was standardized uptake value (SUV), calculated using tissue
radioactivity concentration from 50 to 70 min after 18F-THK5351 injection, normalizing for body weight and injected
radioactivity. The SUV ratio (SUVR) was determined using the cerebellar cortex as the reference region. 18F-THK5351
competition autoradiography studies in postmortem tissue were conducted using 150 and 500 nM selegiline.
Results: At baseline, 18F-THK5351 SUVs were highest in the basal ganglia (0.64 ± 0.11) and thalamus (0.62 ± 0.14). In
the post-selegiline scans, the regional SUVs were reduced on average by 36.7% to 51.8%, with the greatest
reduction noted in the thalamus (51.8%) and basal ganglia (51.4%). MAO-B inhibition also reduced 18F-THK5351
SUVs in the cerebellar cortex (41.6%). The SUVs remained reduced in the three patients imaged at 9–28 days. Tissue
autoradiography confirmed the effects of MAO-B inhibition on 18F-THK5351 uptake.
Conclusions: These results indicate that the interpretation of 18F-THK5351 PET images, with respect to tau, is
confounded by the high MAO-B availability across the entire brain. In addition, the heterogeneous MAO-B
availability across the cortex may limit the interpretation of 18F-THK5351 scans using reference region methods.
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Background
In vivo characterization of tau pathology using positron
emission tomography (PET) constitutes a new frontier
in Alzheimer’s disease (AD) research [1]. It is expected
that tau imaging agents will provide the means for sta-
ging disease progression as well as selecting patients ap-
propriate for a given therapy, confirming the mechanism
of action of pharmacological interventions affecting tau
aggregates and monitoring treatment efficacy for AD [2].
18F-THK5351 is a quinoline-derivative tau imaging
tracer with affinity to paired helical filaments (PHF), a
typical tau aggregate present in neurofibrillary tangles
(NFTs). 18F-THK5351 retention in the temporal lobes in
vivo is able to distinguish AD patients from healthy indi-
viduals [3]. However, 18F-THK5351 is also retained in
the basal ganglia and other brain regions known to ex-
press negligible amounts of PHF, a phenomenon attrib-
utable to off-target binding, which raises concerns about
the specificity of 18F-THK5351 for PHF. Rather than
PHF, the basal ganglia typically express high concentra-
tions of aminergic projections, neuroreceptors, and their
degrading enzymes such as monoamine oxidase (MAO)
[4, 5]. As such, it is plausible to hypothesize that MAO-
B (EC 1.4.3.4) constitutes a 18F-THK5351 off-target
binding site, particularly given its previous reported af-
finity to quinolone derivatives [6]. Furthermore, the
presence of high concentrations of MAO-B in the hu-
man cortex demands a careful examination of the im-
pact of MAO-B binding on 18F-THK5351 images.
Selegiline is an irreversible MAO-B inhibitor utilized to
enhance dopaminergic neurotransmission in Parkinson’s
disease patients [7]. Previous PET studies revealed a
persistent MAO-B inhibition following a single adminis-
tration of MAO-B inhibitors [4]. As such, an acute selegi-
line challenge constitutes an interesting strategy to probe
the contribution of brain MAO-B availability to the
18F-THK5351 uptake observed in patient populations.
Here, in a longitudinal observation of patients with
baseline and post-selegiline 18F-THK5351 PET scans, we
tested the hypothesis that a reduction of MAO-B avail-
ability also reduces 18F-THK5351 uptake. We further




Eight individuals (five mild cognitive impairment (MCI),
two AD, and one progressive supranuclear palsy (PSP))
were recruited. All study participants were screened to
exclude any underlying neuropsychiatric diseases such as
depression and concomitant intake of MAO inhibitors.
Study participants then underwent a Mini-Mental State
Examination (MMSE) [8] and Montreal Cognitive As-
sessment (MoCA) [9]. The MCI, AD, and PSP diagnoses
were made using the Petersen’s [10], National Institute
of Neurological and Communicative Disorders and
Stroke and the Alzheimer’s disease and Related
Disorders Association (NINCDS-ADRDA) [11], and the
National Institute of Neurological Disorders and Stroke
and the Society for PSP (NINDS-SPSP) [12] criteria,
respectively.
Scanning protocol
All eight participants had baseline 18F-AZD4694 and
18F-THK5351 PET scans to quantify brain amyloid and
PHF load, respectively. A second 18F-THK5351 scan was
conducted 1 week later, 1 h after an oral dose of 10 mg
selegiline. Participants were also invited to undergo an
optional third 18F-THK5351 PET scan 10 days after the
selegiline administration. Each 18F-THK5351 acquisition
consisted of dynamic images (4 × 5 min) acquired at 50–
70 min after intravenous bolus injection. The mean ±
standard deviation injected radioactivity of 18F-THK5351
was 6.6 ± 0.3 mCi for the baseline scan, 6.7 ± 0.4 mCi for
the post-selegiline scan, and 6.9 ± 0.4 mCi for the third
scan. 18F-AZD4694 acquisition consisted of dynamic im-
ages (6 × 5 min) acquired at 40–70 min after intravenous
bolus injection of 18F-AZD4694. The injected radioactiv-
ity of 18F-AZD4694 was 6.3 ± 0.3 mCi. A 6-min trans-
mission scan was acquired at the end of each PET scan.
All PET scans were performed using the Siemens High
Resolution Research Tomograph (HRRT). A magnetic
resonance imaging (MRI) anatomical scan was also
performed for all patients using the 1.5 T Siemens
Sonata scanner for co-registration purposes.
18F-THK5351 and 18F-AZD4694 synthesis
18F-THK5351 was synthesized according to a previously
published paper [3], with an average specific activity of
24.3 Ci/μmol for the baseline scan, 19.2 Ci/μmol for the
post-selegiline scan, and 13.5 Ci/μmol for the third scan.
The average injected mass dose was 5.58 ng/kg for the
baseline scan, compared with 6.68 ng/kg for the post-
selegiline scan (P = 0.61, not significant), and 4.21 ng/kg
for the third scan (P = 0.39, not significant). 18F-
AZD4694 was synthesized using a modified synthesis
procedure previously described [13], with an average
specific activity of 6.1 Ci/μmol.
PET and MRI image processing
T1-weighted MRI images were processed using the
CIVET image processing pipeline [14, 15] for field
distortions correction, and the PET images were proc-
essed using an established image processing pipeline
[16]. Briefly, using transformations obtained from PET
native to MRI native space and the MRI native to the
Montreal Neurological Institute (MNI) 152 space, the
PET images were linearly registered and subsequently
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spatially normalized to the MNI 152 standardized space.
The primary outcome measure was the standardized up-
take value (SUV). SUVs were calculated using tissue
radioactivity concentration data from 50 to 70 min
following 18F-THK5351 injection, and 40 to 70 min fol-
lowing 18F-AZD4694 injection, normalized by body
weight and injected radioactivity. The baseline and post-
selegiline 18F-THK5351 SUVs in the cortical gray matter
of the frontal, parietal, lateral temporal, and occipital
lobes, hippocampus, cingulate gyri, basal ganglia, thal-
amus, and cerebellar cortex of each individual were mea-
sured. We then calculated the average percentage
reduction of mean regional SUV in the post-selegiline
scans. The 18F-THK5351 SUV ratio (SUVR) and
18F-AZD4694 SUVR were obtained using the cerebellar
cortex and cerebellum as reference regions, respectively.
The 18F-AZD4694 SUVR images were assessed by two
independent experts (JPS and PRN) to visually classify
the participants as amyloid-positive or amyloid-negative
after full agreement was reached. In a clinical validation
of 18F-AZD4694 using the cerebellum as the reference
region, the SUVRs in AD patients varied between 2.10
and 2.88 across regions [13].
Autoradiography
In vitro autoradiography was performed on 14 postmor-
tem brain sections (seven AD patients with a diagnosis
confirmed by pathological assessment, and seven age-
matched healthy controls) as previously described [17].
In brief, baseline and R-(–)-deprenyl hydrochloride com-
petition experiments were performed on adjacent brain
sections (20 μm thickness). Prepared frozen brain tissues
were warmed to room temperature, air-dried, and pre-
incubated in a buffer saline solution (138 mM NaCl and
27 mM KCl, pH 7.4 adjusted by NaOH) and 1% bovine
serum albumin for 20 min. Brain tissues were then air-
dried and incubated with 18F-THK5351 (1.85 μCi) and
the R-(–)-deprenyl hydrochloride challenge was per-
formed at concentrations of 150 nM and 500 nM for
150 min. After the incubation, brain tissues were dipped
three times in the buffer solution for 3 min each time,
once in 4 °C water for 30 s, and dried under a stream of
cool air. The brain sections were subsequently exposed
to a radioluminographic imaging plate (Fujifilm BAS-
MS2025) for 20 min and obtained using FUJIFILM
BAS-5000. Activity in photostimulated luminescence
units per mm2 was measured using Image Gauge 4.0
(Fujifilm) and the percentage of 18F-THK5351 total
binding after R-(–)-deprenyl hydrochloride challenge
was calculated.
Statistical analysis
The statistical analysis was performed using GraphPad
Prism Version 7.0b (GraphPad Software, La Jolla, Cali-
fornia, USA; www.graphpad.com). The baseline and the
post-selegiline regional 18F-THK5351 SUVs were com-
pared using paired t test analyses. The Bonferroni cor-
rection was used to correct the aforementioned analyses
for multiple comparisons.
Results
Baseline demographics and global 18F-AZD4694 SUVR
of the study participants are summarized in Table 1.
Patients 4, 5 and 8 are classified as amyloid-negative and
patients 1, 2, 3, 6, and 7 are classified as amyloid-
positive (Fig. 1).
The 18F-THK5351 SUV map demonstrated an average
of 36.7 to 51.8% regional uptake reduction in the post-
selegiline scans from the baseline scans (Fig. 1). At base-
line, the mean SUVs were highest in the basal ganglia
(0.64 ± 0.11) followed by the thalamus (0.62 ± 0.14)
(Fig. 2). In the post-selegiline scans, there were statisti-
cally significant regional SUV declines compared to the
baseline scans. The SUV reduction was greatest in the
thalamus (51.8%), followed by the basal ganglia (51.4%).
MAO-B inhibition also reduced 18F-THK5351 SUVs in
the cerebellar cortex (41.6%).
In the three MCI individuals who underwent a third
18F-THK5351 PET scan 9–28 days after the selegiline ad-
ministration, the SUV remained reduced (Fig. 3). There
was no consistent regional 18F-THK5351 SUVR reduc-
tion in the post-selegiline scans from baseline (Figs. 3
and 4), which is in line with the anticipated differences
in the PHF to MAO-B ratio in different brain regions of
Table 1 Baseline demographics
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8
Diagnosis MCI MCI MCI MCI MCI AD AD PSP
Age (years) 71 78 68 59 72 63 55 68
Gender Female Male Female Female Male Male Female Male
MMSE 30 29 30 29 29 15 16 29
MoCA 21 24 27 28 24 6 2 23
Global 18F-AZD4694 SUVR 2.19 1.89 1.73 0.96 0.94 2.64 2.24 1.04
AD Alzheimer’s disease, MCI mild cognitive impairment, MMSE Mini-Mental State Examination, MoCA Montreal Cognitive Assessment, PSP progressive supranuclear
palsy, SUVR standardized uptake value ratio
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different participants, including the cerebellar cortex
reference region.
Autoradiography in postmortem brain sections of AD
patients and healthy controls further demonstrated a
reduction of total 18F-THK5351 uptake following 150
nM and 500 nM R-(–)-deprenyl hydrochloride challenge
(Fig. 5a). This reduction was greater in the striatum, a
region rich in MAO-B but with negligible PHF, than in
the prefrontal cortex and hippocampus where both PHF
and MAO-B are present (Fig. 5b).
Fig. 1 Selegiline reduces brain 18F-THK5351 standardized uptake value. Standardized uptake value (SUV) and SUV ratio (SUVR) map overlaid on a
structural MRI scan showing the SUVR from 40 to 70 min after 18F-AZD4694 injection, and baseline and 1 h post-selegiline SUV from 50 to 70 min
after 18F-THK5351 injection in the eight patients. AD Alzheimer’s disease, MCI mild cognitive impairment, MMSE Mini-Mental State Examination,
MoCA Montreal Cognitive Assessment, PSP progressive supranuclear palsy, y.o years old
Fig. 2 Regional 18F-THK5351 standardized uptake value declines in the post-selegiline scans. Whisker plot showing significant differences between
baseline and 1 h post-selegiline regional standardized uptake value (SUV) in the brain regions 50 to 70 min after 18F-THK5351 injection in the
eight patients. Cerebellar cortex: P = 0.001; thalamus: P = 0.001; basal ganglia: P < 0.001; hippocampus: P = 0.003; cingulate: P < 0.001; parietal:
P < 0.001; lateral temporal: P = 0.001; frontal: P < 0.001; occipital: P < 0.001. BL baseline, PS post-selegiline
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Discussion
In summary, we showed that brain and cerebellar cortex
MAO-B availability affects 18F-THK5351 SUV. Follow-
ing a single 10 mg oral dose of selegiline, 18F-THK5351
SUVs decreased by approximately 30 to 50% depending
on the brain region, with the highest decline noted in
the basal ganglia and thalamus which are known to ex-
press the highest concentrations of MAO-B in the brain
[4]. The in vitro autoradiography blocking experiments
showed similar effects. The long-lasting selegiline-
evoked 18F-THK5351 SUV decline indicates MAO-B
inhibition as the possible mechanism underlying this
effect.
MAO-B is a protein highly expressed in all brain re-
gions. It is compartmentalized in the outer membrane of
the astrocytes mitochondria [18]. During the normal
aging process, global MAO-B availability increases at the
rate of nearly 9% per decade [19, 20]. In fact, MAO-B
imaging has been proposed as a biomarker for astrocyto-
sis in various neurodegenerative conditions associated
with cell death or activation of immune responses, with
some investigators reporting higher MAO-B binding in
Fig. 3 The reduction of 18F-THK5351 standardized uptake value remains in the second follow-up. Standardized uptake value (SUV) and SUV ratio
(SUVR) map overlaid on a structural MRI scan showing the baseline, 1 h and 9–28 days post-selegiline SUV and SUVR from 50 to 70 min after
18F-THK5351 injection in three patients. MCI mild cognitive impairment, y.o years old
Fig. 4 The effects of selegiline in cerebellum mask the reduction of 18F-THK5351 standardized uptake value ratio. Standardized uptake value ratio
(SUVR) map overlaid on a structural MRI scan showing the baseline and 1 h post-selegiline SUVR from 50 to 70 min after 18F-THK5351 injection in
the eight patients. AD Alzheimer’s disease, MCI mild cognitive impairment, PSP progressive supranuclear palsy, y.o years old
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AD patients versus aged-matched controls [21–23].
Moreover, MAO-B inhibition has significant therapeutic
effects for mood disorders and Parkinson’s disease, and
it is considered a therapeutic target for various neurode-
generative conditions [24].
The high retention of tau imaging agents such as 18F-
THK5351 and 18F-flortaucipir to brain structures known
to be devoid of PHF has been attributed to off-target
binding sites. It is important to emphasize that off-target
binding implies specific (saturable) binding of the im-
aging agent to proteins other than the primary target for
which it was intended. Generally, it is desirable that the
affinity of the target binding sites be higher by at least
one order of magnitude as compared to that of the off-
target binding sites, although the lack of such a specifi-
city might be acceptable if the target and off-target
binding sites do not coexist in the same brain region
[25]. Our results suggest that 18F-THK5351 binds to
MAO-B and PHF with similar affinity, which might be
detrimental to PHF quantification in the brain. However,
given that 18F-THK5351 is biochemically different from
18F-flortaucipir, our findings cannot be generalized.
Interestingly, the acute selegiline challenge conducted
in this study evoked the highest 18F-THK5351 SUV de-
cline in the thalamus and striatum, which express high
levels of MAO-B [4], and are also known to be devoid of
PHF. However, it is worth mentioning that the magni-
tude of MAO-B inhibition in the aforementioned
regions was variable, as described by previous studies
[26, 27]. This variability can be attributed to individual
differences in selegiline absorption, biodistribution, or
pharmacodynamics. Furthermore, the exposure to
MAO-B inhibitors present in tobacco, certain antide-
pressants, or herbal therapies may also influence such
variability [28, 29].
The long-lasting effects of selegiline support MAO-B
inhibition as the main mechanism involved in the effects
observed by this study. Indeed, previous studies
conducted in vivo estimate that the de novo synthesis
half-life of MAO-B is 40 days [30]. Our autoradiography
results conducted in postmortem brain of AD patients
(Fig. 5) also support 18F-THK5351 binding to both
MAO-B and PHF. Importantly, the enrolment of a clin-
ically heterogeneous population in this study was
intended to test whether MAO-B availability affects 18F-
THK5351 SUV independently of other specific patho-
physiological processes.
The selegiline challenge in the present study affected
cortical 18F-THK5351 SUVs (Fig. 1) in regions known to
accumulate PHF, such as the mesial basal temporal, tem-
poral, and parietal cortices [31]. These regions also
express high concentrations of MAO-B [5]. The visual
assessments of 18F-THK5351 SUV images obtained in
amyloid-positive individuals revealed the signature previ-
ously described in AD patients [2], which remained after
the challenge with selegiline. Similarly, the high uptake
Fig. 5 18F-THK5351 autoradiography competition with R-(–)-deprenyl hydrochloride shows dose-dependent uptake decline. a In vitro
autoradiography of the postmortem striatum, prefrontal cortex, and hippocampal brain sections of Alzheimer’s disease (AD) patients and controls
showing the reduction of baseline 18F-THK5351 binding after 150 nM and 500 nM R-(–)-deprenyl hydrochloride challenge. b Reduction of
percentage of 18F-THK5351 total uptake is greater in the striatum than in the prefrontal cortex and hippocampus
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in the midbrain and basal ganglia of our patient with
PSP remained after the post-selegiline scan. This may
support the concept that 18F-THK5351 binds to 4-R tau
pathology in the midbrain and basal ganglia, which is
consistent with the imaging signature recently described
[32]. The AD and PSP signatures observed after the sele-
giline challenge represent images with decreased effects
of MAO-B availability.
We found that cerebellar cortex 18F-THK5351 SUVs
declined to a lesser extent as compared to cerebral cor-
tical regions following the selegiline challenge. This
observation is consistent with previous studies showing
declines in cerebellar MAO-B availability following
pharmacological inhibition [5, 33]. In our study, the
quantification of 18F-THK5351 uptake using SUVR with
the cerebellar cortex as a reference region was also
sensitive to the selegiline challenge. Although cerebellar
MAO-B availability invalidates the use of this region as a
reference to derive 18F-THK5351 SUVR in the context
of this study, future research should focus on method-
ology to correct MAO-B bias in 18F-THK5351 SUVR
measurements [34].
The use of imaging agents with low specificity is ac-
ceptable to analyze PET images from brain regions with-
out off-target binding sites [35, 36]. However, the
interpretation of PET data obtained using tracers with
low specificity becomes challenging when target and off-
target binding sites co-localize within specific anatomical
regions. In this situation, the major issue is obtaining
PET signals of interest without the confounding effects
from off-target sites. Tracer specificity becomes even
more important in the case of imaging agents targeting
abnormal protein aggregates. At early stages of the dis-
ease, when the load of abnormal protein aggregates is
negligible, as compared to the availability of off-target
binding sites, one could expect a higher confounding
signal from the off-target binding [5, 37]. By contrast, in
later stages of the disease, the relative contribution of
off-target binding is reduced given the higher concentra-
tions of protein aggregates in the tissue, despite high
concentrations of MAO-B in the hippocampus, temporal
neocortex, and cingulate gyrus [5]. It is also worth not-
ing that the visual appearance of 18F-THK5351 PET
images is not inconsistent with the pathological distribu-
tion of NFTs reported in Braak staging [38]. The poten-
tial reason for this is that, as neurons are compromised
by NFTs, astrocytosis ensues in these regions [31]. The
increase of MAO-B is likely due to astrocytosis in
response to NFTs, and the PET signals here could be
considered as a combination of both PHF and astrocyto-
sis. This would need to be verified by future studies.
The interpretation of these results should take into
consideration the following methodological limitations.
Firstly, the present study was not conducted using full
dynamic scans with an arterial input function, but relied
on the SUV measured on 18F-THK5351 images obtained
from 50 to 70 min after tracer injection [3] which is sus-
ceptible to physiological sources of variability. Secondly,
although previous studies show that chronic administra-
tion of selegiline does not significantly affect cerebral
blood flow, it has been reported that acute selegiline ad-
ministration may induce rapid brain vasodilation via
nitric oxide release [39]. Hence, it is possible that the
selegiline dose in the present study may induce cerebral
blood flow changes and affect accurate quantification of
18F-THK5351 uptake.
Conclusions
The present study supports the concept that MAO-B is
an 18F-THK5351 off-target binding site. As such, the
current methods for analyzing 18F-THK5351 inevitably
incorporate undesired confounding signal from MAO-B
availability, which probably dominates PET signals in
early stages of AD. Therefore, it would be appropriate
for the methods used to quantify 18F-THK5351 to take
into account the cortical MAO-B signal. Importantly,
heterogeneous MAO-B availability across the cortex
may also limit the quantification of 18F-THK5351 uptake
using reference brain regions. In addition, with regards
to the use of 18F-THK5351 in longitudinal studies and
clinical trials in AD, one should be aware that both
MAO-B and tau binding may increase with age at differ-
ent rates in different brain regions of different individ-
uals, whilst tau binding will increase in the same fashion
with disease progression, or potentially decrease in
response to an efficacious treatment. As such, experi-
ments should be designed and interpreted with care to
account for these processes. Finally, it is important to
emphasize that the confounding effect of MAO-B avail-
ability in patients with high loads of PHF should be
further evaluated by subsequent studies.
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